Lung cancer screening in Australia and New Zealand: the evidence and the challenge

Lung Cancer Screening Participation Among Indigenous Peoples Worldwide: A Systematic Review of Challenges and Opportunities

ISSUE ADDRESSED

Lung cancer screening (LCS) is crucial for Indigenous populations due to their higher lung cancer incidence rates and poorer outcomes. Despite efforts to establish LCS programmes, evidence on LCS cost-effectiveness, participation rates, facilitators and barriers for Indigenous peoples remains limited. This systematic review aims to address this gap by reviewing available evidence.

METHODS

This systematic review conducted searches for relevant articles in PubMed, Scopus, CINAHL, Google Scholar and references/citations of included articles.

RESULTS

Fifteen out of 19 eligible studies were conducted in the USA, three in New Zealand and one in Canada, with 23 715 Indigenous participants in the 15 quantitative studies. New Zealand studies found that LCS is cost-effective for Māori, while the participation rate for American Indian/Alaska Natives (4.7%) was lower than for White Americans (21.7%). Facilitators included positive views of LCS, trust in Indigenous-centred care/providers, trusted invitations, family and community support, transportation or flexible scheduling, culturally competent navigators and detailed health education. Barriers included limited knowledge about LCS/eligibility criteria, fear of the screening process or cancer diagnosis, mistrust or negative experiences in healthcare, cost and time constraints, limited transportation/resources and non-inclusive eligibility criteria.

CONCLUSIONS

Further research is needed to understand the LCS among Indigenous peoples. Enhancing LCS participation requires leveraging positive experiences and addressing barriers with culturally tailored education and strategic resource allocation. SO WHAT?: For Australia and similar countries preparing for LCSPs, global evidence highlights the need for adequate resources, integration of Indigenous cultural practices and active involvement of Indigenous communities in programme planning.

Ethnic differences in the characteristics of patients with newly diagnosed lung cancer in the Te Manawa Taki region of New Zealand

BACKGROUND

Māori have three times the mortality from lung cancer compared with non-Māori. The Te Manawa Taki region has a population of 900 000, of whom 30% are Māori. We have little understanding of the factors associated with developing and diagnosing lung cancer and ethnic differences in these characteristics.

AIMS

To explore the differences in the incidence and characteristics of patients with newly diagnosed lung cancer between Māori and non-Māori.

METHODS

Patients were identified from the regional register. Incidence rates were calculated based on population data from the 2013 and 2018 censuses. The patient and tumour characteristics of Māori and non-Māori were compared. The analysis used Χ2 tests and logistic models for categorical variables and Student t tests for continuous variables.

RESULTS

A total of 4933 patients were included, with 1575 Māori and 3358 non-Māori. The age-standardised incidence of Māori (236 per 100 000) was 3.3 times higher than that of non-Māori. Māori were 1.3 times more likely to have an advanced stage of disease and 1.97 times more likely to have small cell lung cancer. Māori were more likely to have comorbidities, chronic obstructive pulmonary disease, cardiovascular disease and diabetes. They also had higher levels of social deprivation and tended to be younger, female and current smokers.

CONCLUSIONS

The findings point to the need to address barriers to early diagnosis and the need for system change including the need to introduce a lung cancer screening focussing on Māori. There is also the need for preventive programmes to address comorbidities that impact lung cancer outcomes as well as a continued emphasis on creating a smoke-free New Zealand.

Invitation methods for Indigenous New Zealand Māori in lung cancer screening: Protocol for a pragmatic cluster randomized controlled trial

Lung cancer screening can significantly reduce mortality from lung cancer. Further evidence about how to optimize lung cancer screening for specific populations, including Aotearoa New Zealand (NZ)'s Indigenous Māori (who experience disproportionately higher rates of lung cancer), is needed to ensure it is equitable. This community-based, pragmatic cluster randomized trial aims to determine whether a lung cancer screening invitation from a patient's primary care physician, compared to from a centralized screening service, will optimize screening uptake for Māori. Participating primary care practices (clinics) in Auckland, Aotearoa NZ will be randomized to either the primary care-led or centralized service for delivery of the screening invitation. Clinic patients who meet the following criteria will be eligible: Māori; aged 55-74 years; enrolled in participating clinics in the region; ever-smokers; and have at least a 2% risk of developing lung cancer within six years (determined using the PLCOM2012 risk prediction model). Eligible patients who respond positively to the invitation will undertake shared decision-making with a nurse about undergoing a low dose CT scan (LDCT) and an assessment for Chronic Obstructive Pulmonary Disease (COPD). The primary outcomes are: 1) the proportion of eligible population who complete a risk assessment and 2) the proportion of people eligible for a CT scan who complete the CT scan. Secondary outcomes include evaluating the contextual factors needed to inform the screening process, such as including assessment for Chronic Obstructive Pulmonary Disease (COPD). We will also use the RE-AIM framework to evaluate specific implementation factors. This study is a world-first, Indigenous-led lung cancer screening trial for Māori participants. The study will provide policy-relevant information on a key policy parameter, invitation method. In addition, the trial includes a nested analysis of COPD in the screened Indigenous population, and it provides baseline (T0 screen round) data using RE-AIM implementation outcomes.

An International Consensus on Actions to Improve Lung Cancer Survival: A Modified Delphi Method Among Clinical Experts in the International Cancer Benchmarking Partnership

BACKGROUND

Research from the International Cancer Benchmarking Partnership (ICBP) demonstrates that international variation in lung cancer survival persists, particularly within early stage disease. There is a lack of international consensus on the critical contributing components to variation in lung cancer outcomes and the steps needed to optimise lung cancer services. These are needed to improve the quality of options for and equitable access to treatment, and ultimately improve survival.

METHODS

Semi-structured interviews were conducted with 9 key informants from ICBP countries. An international clinical network representing 6 ICBP countries (Australia, Canada, Denmark, England, Ireland, New Zealand, Northern Ireland, Scotland & Wales) was established to share local clinical insights and examples of best practice. Using a modified Delphi consensus model, network members suggested and rated recommendations to optimise the management of lung cancer. Calls to Action were developed via Delphi voting as the most crucial recommendations, with Good Practice Points included to support their implementation.

RESULTS

Five Calls to Action and thirteen Good Practice Points applicable to high income, comparable countries were developed and achieved 100% consensus. Calls to Action include (1) Implement cost-effective, clinically efficacious, and equitable lung cancer screening initiatives; (2) Ensure diagnosis of lung cancer within 30 days of referral; (3) Develop Thoracic Centres of Excellence; (4) Undertake an international audit of lung cancer care; and (5) Recognise improvements in lung cancer care and outcomes as a priority in cancer policy.

CONCLUSION

The recommendations presented are the voice of an expert international lung cancer clinical network, and signpost key considerations for policymakers in countries within the ICBP but also in other comparable high-income countries. These define a roadmap to help align and focus efforts in improving outcomes and management of lung cancer patients globally.

New lung cancer diagnosis after emergency department presentation in a tertiary hospital: patient characteristics and outcomes

OBJECTIVES

Currently there is limited data available about patients who are diagnosed with lung cancer following an emergency department (ED) visit. This study sought to define the demographics, symptoms profile, staging, and prognosis of this cohort of patients.

METHODS

We conducted a retrospective study of patients diagnosed with a primary lung malignancy at a lung cancer multi-disciplinary meeting between January 2018-January 2020. Medical records were reviewed to collect data around demographics, presenting symptoms, investigations, admission, cancer stage, and mortality.

RESULTS

During the study period, 890 patients were diagnosed with a primary lung malignancy of which 209 (23.5%) presented to ED prompting diagnostic work-up. Of these 209 patients, 89% were hospitalised for a median duration of 6 days. 104 (50%) were female and average age of cohort was 70 years. Dyspnoea (38%) was the most common presenting symptom. Radiological staging and tissue biopsy was performed as an outpatient procedure in 46% and 41% of patients respectively. 188 patients had non-small cell lung cancer of whom 68% had Stage IV disease. 53 (25%) patients died within 3 months of ED presentation. These patients were older with more advanced disease compared to patients who were alive at 3 months.

CONCLUSION

: Emergent diagnosed patients are a significant proportion of the lung cancer population, presenting with advanced stage disease and increased short-term mortality. Future research should be directed at interventions, such as lung cancer screening program and/or community education to reduce the need for patients to present the emergency department with disabling lung cancer symptoms.